Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 17 April, 2020

STRATEC SE

STRATEC POSTPONES 2020 ANNUAL GENERAL MEETING

DGAP-News: STRATEC SE / Key word(s): AGM/EGM
STRATEC POSTPONES 2020 ANNUAL GENERAL MEETING

17.04.2020 / 08:27
The issuer is solely responsible for the content of this announcement.


STRATEC POSTPONES 2020 ANNUAL GENERAL MEETING

Birkenfeld, April 17, 2020

Given the latest developments concerning the spread of coronavirus (SARS-CoV-2), STRATEC SE is postponing its Annual General Meeting, which was originally scheduled to take place in Pforzheim on May 20, 2020, to June 8, 2020.

To protect the health of all involved, the company's management has also decided to hold this year's Annual General Meeting without shareholders or their authorized representatives being physically present. The basis for this kind of virtual Annual General Meeting (online AGM) is provided by the legislation enacted in March 2020 to mitigate the effects of the COVID 19 pandemic on civil law, insolvency law, and criminal law.

As already communicated on April 2, 2020, the Board of Management and the Supervisory Board of STRATEC plan to propose a dividend payment of € 0.84 per share for the 2019 financial year (previous year: € 0.82 per share) for approval by the Annual General Meeting. Subject to approval by shareholders, this would mark the sixteenth consecutive rise in STRATEC's dividend since payment of the first dividend in 2004.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers integrated laboratory software and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, Investor Relations & Corporate Communications
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190
[email protected]
www.stratec.com



17.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1023133

 
End of News DGAP News Service

1023133 17.04.2020 

fncls.ssp?fn=show_t_gif&application_id=1023133&application_name=news&site_id=financialexpress

a d v e r t i s e m e n t